28,564 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 28,564 shares of the company's stock, valued at approximately $538,000.

Several other institutional investors have also recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its position in Nurix Therapeutics by 32.4% during the third quarter. The Manufacturers Life Insurance Company now owns 30,383 shares of the company's stock worth $683,000 after buying an additional 7,441 shares in the last quarter. FMR LLC increased its position in Nurix Therapeutics by 675.9% during the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock worth $13,188,000 after purchasing an additional 511,256 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new stake in Nurix Therapeutics during the 3rd quarter worth about $607,000. Quarry LP raised its stake in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $56,000 after purchasing an additional 2,435 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Nurix Therapeutics by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after purchasing an additional 280,240 shares in the last quarter.

Wall Street Analysts Forecast Growth

NRIX has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Needham & Company LLC cut their price target on Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday. Morgan Stanley raised their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. BTIG Research started coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $35.00 target price for the company. Finally, Stifel Nicolaus decreased their price target on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.44.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock traded up $0.34 during midday trading on Wednesday, hitting $9.60. 2,274,137 shares of the company were exchanged, compared to its average volume of 918,362. The company has a market cap of $731.87 million, a PE ratio of -3.32 and a beta of 2.23. Nurix Therapeutics, Inc. has a fifty-two week low of $8.56 and a fifty-two week high of $29.56. The company's fifty day moving average price is $14.42 and its 200-day moving average price is $19.39.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the company posted ($0.76) earnings per share. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company's stock, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock valued at $213,449 in the last ninety days. Insiders own 9.80% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.